



# CORONAVAC

Italo Cavalho  
Dawidson Pereira  
Ênrell Jeronimo  
Ivan Teotônio



# What is?

CORONAVAC IS A VACCINE AGAINST COVID-19 DEVELOPED BY  
THE CHINESE BIOPHARMACEUTICAL COMPANY SINOVAC  
BIOTECH. THE VACCINE USES A DEACTIVATED SARS-COV-2 VIRUS  
ANTIGEN, THE TYPE OF CORONAVIRUS THAT CAUSES COVID-19.



# DATA

The initial phase of the research in Brazil showed that, if a person is infected with covid-19, CORONAVAC is 100% effective in preventing serious sickness, 78% in preventing mild cases and reducing the risk of becoming ill by 50.39%.



# IT'S SAFE?

## Adverse reactions very common in 10% of patients:

Application site: mild pain at the application site.

## Common reactions, between 1% to 10% of patients:

Systemic: fatigue, fever, myalgia, diarrhea, nausea, headache.

## Unusual reaction 0.1% and 1% of patients:

Local: abnormal coloring at the injection site, swelling, pruritus, erythema, local hypoesthesia, induration.

Systemic: vomiting, lower abdominal pain, bloating, dizziness, cough, loss of appetite, hypersensitivity, high blood pressure, allergic or immediate hypersensitivity.



# IT'S SAFE?

Intensity of Adverse Reactions: The intensities of adverse reactions observed in phase I/II clinical trials with this product in adults over 18 years of age were grade 1 (mild) and grade 2 (moderate), and the incidence was 23.73 % and 1.94%, respectively. No Grade 3 (severe) adverse reactions occurred. Most adverse reactions recovered within one week. No serious adverse events related to vaccination with this product were found.



# REACTIONS

- The most common reaction observed after the second dose of vaccine in both groups was pain at the injection site, which occurred in 40.1% of adults and 27.8% of the elderly;
- The vast majority of adverse reactions observed were Grade 1 or 2 and no serious adverse reactions occurred;



# REFERENCES

Updated leaflet:

<https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/bulas-e-rotulos/bulas-uso-emergencial/vacinas/bula-coronavac-atualizada.pdf>

Authorization for use in Brazil:

<https://www.gov.br/anvisa/pt-br/assuntos/paf/noticias-anvisa/2021/confira-materiais-da-reuniao-extraordinaria-da-dicol/1-apresentacao-ggmed-coronavac.pdf>